Advertisement

Age-Related Differences in Oncological Outcomes in Renal Cell Carcinoma: Impact of Functional Conservation as Measured by Postoperative eGFR

Published:December 06, 2022DOI:https://doi.org/10.1016/j.clgc.2022.12.002

      Abstract

      Introduction

      We sought to determine whether loss of renal function increases risk of recurrence and metastases in renal cell carcinoma (RCC), and whether this impact was age-related.

      Materials and Methods

      We performed a retrospective analysis of the International Marker Consortium for Renal Cancer (INMARC) registry. Patients were separated into younger (<65 years old) and elder (≥65 years old) age groups, and rates of de novo estimated glomerular filtration rate (eGFR<45 mL/min/1.73m2 [eGFR<45]) were calculated. Multivariable analysis (MVA) was conducted for predictors of progression-free survival (PFS) and all-cause mortality (ACM). Kaplan-Meier Analysis (KMA) was conducted for PFS and overall survival (OS) in younger and elder age groups stratified by functional status.

      Results

      We analyzed 1805 patients (1113 age<65, 692 age≥65). On MVA in patients <65, de novo eGFR<45 was independently associated with greater risk for worsened progression (HR=1.61, P=.038) and ACM (HR=1.82, P=.018). For patients ≥65, de novo eGFR<45 was not independently associated with progression (P=.736), or ACM (P=.286). Comparing patients with de novo eGFR<45 vs. eGFR ≥45, KMA demonstrated worsened 5-year PFS and OS in patients <65 (PFS: 68% vs. 86%, P<.001; OS: 73% vs. 90%, P<.001), while in patients ≥65, only 5-year OS was worsened (77% vs. 81%, P<.021).

      Conclusion

      Development of de novo eGFR<45 was associated with more profound impact on patients <65 compared to patients ≥65, being an independent risk factor for PFS and ACM. The mechanisms of this phenomenon are unclear but underscore desirability for nephron preservation when safe and feasible in younger patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F
        • Ferlay J
        • Soerjomataram I
        • Siegel RL
        • Torre LA
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries published correction appears in.
        CA Cancer J Clin. 2020; 70: 313https://doi.org/10.3322/caac.21492
        • Padala SA
        • Barsouk A
        • Thandra KC
        • et al.
        Epidemiology of renal cell carcinoma.
        World J Oncol. 2020; 11: 79-87https://doi.org/10.14740/wjon1279
        • Pinthus JH
        • Whelan KF
        • Gallino D
        • Lu JP
        • Rothschild N.
        Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.
        Can Urol Assoc J. 2011; 5: 274-282https://doi.org/10.5489/cuaj.10196
        • Lowrance WT
        • Ordoñez J
        • Udaltsova N
        • Russo P
        Go AS. CKD and the risk of incident cancer.
        J Am Soc Nephrol. 2014; 25: 2327-2334https://doi.org/10.1681/ASN.2013060604
        • Cairns P.
        Renal cell carcinoma.
        Cancer Biomark. 2010; 9: 461-473https://doi.org/10.3233/CBM-2011-0176
        • Sung H
        • Ferlay J
        • Siegel RL
        • et al.
        Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA: Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
        • Campbell SC
        • Clark PE
        • Chang SS
        • Karam JA
        • Souter L
        • Uzzo RG.
        Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I.
        J Urol. 2021; 206 (-08): 199https://doi.org/10.1097/JU.0000000000001911
        • Huang WC
        • Levey AS
        • Serio AM
        • et al.
        Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.
        Lancet Oncol. 2006; 7: 735-740https://doi.org/10.1016/S1470-2045(06)70803-8
        • Malcolm JB
        • Bagrodia A
        • Derweesh IH
        • et al.
        Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy.
        BJU Int. 2009; 104: 476-481https://doi.org/10.1111/j.1464-410X.2009.08376.x
        • Mir MC
        • Derweesh I
        • Porpiglia F
        • Zargar H
        • Mottrie A
        • Autorino R.
        Partial nephrectomy versus radical nephrectomy for clinical t1b and t2 renal tumors: a systematic review and meta-analysis of comparative studies.
        Eur Urol. 2017; 71: 606-617https://doi.org/10.1016/j.eururo.2016.08.060
        • Simmons MN
        • Weight CJ
        • Gill IS.
        Laparoscopic radical versus partial nephrectomy for tumors >4 cm: intermediate-term oncologic and functional outcomes.
        Urology. 2009; 73: 1077-1082https://doi.org/10.1016/j.urology.2008.11.059
        • Nguyen MV
        • Walia A
        • Saidian A
        • et al.
        Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma.
        BJU Int. 2022; https://doi.org/10.1111/bju.15861
        • Lane BR
        • Demirjian S
        • Derweesh IH
        • et al.
        Survival and functional stability in chronic kidney disease due to surgical removal of nephrons: importance of the new baseline glomerular filtration rate.
        Eur Urol. 2015; 68: 996-1003https://doi.org/10.1016/j.eururo.2015.04.043
        • Pettus JA
        • Jang TL
        • Thompson RH
        • Yossepowitch O
        • Kagiwada M
        • Russo P.
        Effect of baseline glomerular filtration rate on survival in patients undergoing partial or radical nephrectomy for renal cortical tumors.
        Mayo Clin Proc. 2008; 83: 1101-1106https://doi.org/10.4065/83.10.1101
        • Cotta BH
        • Meagher MF
        • Patil D
        • et al.
        Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC).
        BJU Int. 2021; 127: 311-317https://doi.org/10.1111/bju.15200
        • Patel SH
        • Derweesh IH
        • Saito K
        • et al.
        Preoperative elevation of c-reactive protein is a predictor for adverse oncologic survival outcomes for renal cell carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC).
        Clin Genitourin Cancer. 2021; 19: e206-e215https://doi.org/10.1016/j.clgc.2021.02.003
        • Paner GP
        • Stadler WM
        • Hansel DE
        • Montironi R
        • Lin DW
        • Amin MB.
        Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers.
        Eur Urol. 2018; 73: 560-569https://doi.org/10.1016/j.eururo.2017.12.018
        • Levey AS
        • Stevens LA
        • Schmid CH
        • et al.
        A new equation to estimate glomerular filtration rate published correction appears in.
        Ann Intern Med. 2011; 155: 408https://doi.org/10.7326/0003-4819-150-9-200905050-00006
        • Antonelli A
        • Minervini A
        • Sandri M
        • et al.
        Below safety limits, every unit of glomerular filtration rate counts: assessing the relationship between renal function and cancer-specific mortality in renal cell carcinoma.
        Eur Urol. 2018; 74: 661-667https://doi.org/10.1016/j.eururo.2018.07.029
        • Antonelli A
        • Palumbo C
        • Sandri M
        • et al.
        Renal function impairment below safety limits correlates with cancer-specific mortality in localized renal cell carcinoma: results from a single-center study.
        Clin Genitourin Cancer. 2020; 18: e360-e367https://doi.org/10.1016/j.clgc.2019.12.005
        • Palacios DA
        • Zabor EC
        • Munoz-Lopez C
        • et al.
        Does reduced renal function predispose to cancer-specific mortality from renal cell carcinoma?.
        Eur Urol. 2021; 79: 774-780https://doi.org/10.1016/j.eururo.2021.02.035
        • Iff S
        • Craig JC
        • Turner R
        • et al.
        Reduced estimated GFR and cancer mortality.
        Am J Kidney Dis. 2014; 63: 23-30https://doi.org/10.1053/j.ajkd.2013.07.008
        • Wu J
        • Suk-Ouichai C
        • Dong W
        • et al.
        Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery.
        BJU Int. 2018; 121: 93-100https://doi.org/10.1111/bju.13994
        • Huang WC
        • Elkin EB
        • Levey AS
        • Jang TL
        • Russo P.
        Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes?.
        J Urol. 2009; 181: 55-62https://doi.org/10.1016/j.juro.2008.09.017
        • Sun M
        • Bianchi M
        • Trinh QD
        • et al.
        Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.
        BJU Int. 2013; 111: 67-73https://doi.org/10.1111/j.1464-410X.2012.11254.x
        • Ristau BT
        • Handorf EA
        • Cahn DB
        • Kutikov A
        • Uzzo RG
        • Smaldone MC.
        Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
        Cancer. 2018; 124: 3839-3848https://doi.org/10.1002/cncr.31582
        • Mir MC
        • Pavan N
        • Capitanio U
        • et al.
        Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project).
        World J Urol. 2020; 38: 151-158https://doi.org/10.1007/s00345-019-02665-2
        • Kim SP
        • Campbell SC
        • Gill I
        • et al.
        Collaborative review of risk benefit trade-offs between partial and radical nephrectomy in the management of anatomically complex renal masses.
        Eur Urol. 2017; 72: 64-75https://doi.org/10.1016/j.eururo.2016.11.038
        • Karakiewicz PI
        • Hutterer GC
        • Trinh QD
        • et al.
        C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.
        Cancer. 2007; 110: 1241-1247https://doi.org/10.1002/cncr.22896
        • Viers BR
        • Houston-Thompson R
        • Boorjian SA
        • Lohse CM
        • Leibovich BC
        • Tollefson MK
        Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy.
        Urol Oncol. 2014; 32: 1277-1284https://doi.org/10.1016/j.urolonc.2014.05.014
        • Wang Z
        • Peng S
        • Wang A
        • et al.
        Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.
        Clin Chim Acta. 2018; 480: 166-172https://doi.org/10.1016/j.cca.2018.02.014